The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care?
- PMID: 1843801
- DOI: 10.1192/bjp.159.5.709
The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care?
Abstract
In a prospective study of 20 patients with NMS, those who received dantrolene (2 patients) or bromocriptine (2 patients) or both (4 patients) tended to have a more prolonged course of illness and a greater incidence of sequelae than those treated with supportive care alone. These results do not indicate a useful role for dantrolene or bromocriptine in the treatment of NMS.
Comment in
-
Neuroleptic malignant syndrome.Br J Psychiatry. 1992 Jun;160:868. doi: 10.1192/bjp.160.6.868a. Br J Psychiatry. 1992. PMID: 1617375 No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
